Physician profile
Carole Spickerman
NPI 1225293673
$1,158.42
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $954 · 2022: $134 · 2023: $69.99.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $69.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $69.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $111.91 | 2021 | |
| Janssen Biotech, INC. | $107.48 | 2021-2023 | Erleada |
| Novartis Pharmaceuticals Corporation | $100.00 | 2021-2022 | |
| Aveo Pharmaceuticals, INC. | $99.95 | 2022 | |
| Merck Sharp & Dohme LLC | $98.86 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $69.02 | 2021 | |
| Pfizer INC. | $63.50 | 2021 | |
| Lilly USA, LLC | $53.78 | 2021 | |
| Seagen INC. | $50.34 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $49.99 | 2021 | |
| Abbvie INC. | $48.42 | 2021 | |
| Incyte Corporation | $47.55 | 2021 | |
| Myovant Sciences INC. | $41.72 | 2021 | |
| Taiho Oncology, INC. | $19.93 | 2021 | |
| Deciphera Pharmaceuticals INC. | $19.56 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $19.42 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $19.27 | 2021 | |
| Puma Biotechnology, INC. | $18.77 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.29 | 2021 | |
| Gilead Sciences, INC. | $16.68 | 2021 | |
| Rigel Pharmaceuticals, INC. | $16.15 | 2021 | |
| Daiichi Sankyo INC. | $14.76 | 2021 | |
| Jazz Pharmaceuticals INC. | $14.59 | 2021 | |
| Janssen Pharmaceuticals, INC | $14.23 | 2021 | |
| Dova Pharmaceuticals | $12.78 | 2021 | |
| Beigene USA, INC. | $12.47 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carole Spickerman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.